ArticleJPRAS open2026
Gas subcision with PDLLA (Juvelook): Evaluating a hybrid mechanical-biologic approach for atrophic acne scars.
Article in JPRAS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrophic acne scars result from impaired dermal repair following inflammation of the pilosebaceous unit, leading to collagen degradation, dermal atrophy, and tethering by fibrotic strands. Conventional subcision mechanically releases these adhesions but provides limited biologic stimulation for dermal remodeling. Carbon dioxide (CO₂) gas subcision has emerged as a hybrid mechanical-biologic modality that integrates fibrotic release with CO₂ -induced vasodilation, microcirculatory enhancement, and fibroblast activation. Objective: To describe the clinical use and short-term outcomes of CO₂ gas subcision for atrophic acne scars and explore its potential as a minimally invasive hybrid treatment. Methods: CO₂ device (Trifill Pro, South Korea) and PDLLA (Juvelook, VAIM Inc., South Korea) was used in the study. A temperature-regulated medical-grade CO₂ system delivered controlled intradermal gas through a 30-gauge needle. Short CO₂ bursts were administered into the deep dermal or upper subcutaneous plane to detach fibrotic bands while inducing hypercapnia-associated biologic responses. Five patients with atrophic acne scars underwent a single session. Follow-up at weeks 2 and 4 included standardized photography, clinical assessment of scar depth and contour, and patient-reported satisfaction using a 0-10 Visual Analogue Scale (VAS). Results: Five patients completed follow-up at 4 weeks. All patients demonstrated qualitative improvement in scar depth and contour on clinical assessment. Mean patient satisfaction score (VAS) was high (range 7-9). No serious adverse events were observed. Mild transient erythema and edema resolved spontaneously within hours. Due to the small sample size and short follow-up, results are descriptive rather than statistically powered. Conclusions: CO₂ gas subcision appears to be a feasible and well-tolerated minimally invasive technique combining mechanical fibrotic release with biologic stimulation. This pilot case series suggests short-term improvement in atrophic acne scars; however, larger controlled studies with longer follow-up are required to confirm efficacy and durability. Evidence level: VBlinded manuscript without author contact information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.